A POSSIBILITY TO USE ANTIARRHYTHMIC MEDICATIONS FROM II CLASS AND MODULATED KINESITHERAPY AS PRIMARY PREVENTION OF ATRIAL FIBRILLATION IN METABOLIC SYNDROME PATIENTS
https://doi.org/10.15829/1560-4071-2015-11-75-80
Abstract
Aim. To evaluate the usage of II class antiarrhythmic drugs and modulated kinesitherapy (MK) as primary prevention of atrial fibrillation (AF) in patients with metabolic syndrome (MS) with revelation of short-term risk for this arrhythmia development.
Material and methods. We observed 153 patients with MS at the age 58-75 y. o. without AF in anamnesis, but with short-term risk of its development (2 years after examination), defined via comparative analysis of AF course, induced by transesophageal electrocardiostimulation, in dynamic patients observation. All patients, as primary prevention of AF, used antiarrhythmics of the 2nd class, and in side effects development or in contraindications they underwent MK; polyunsaturated fatty acids also used (PUFA).
Results. After inclusion to the study 77 (50,33%) of MS patients used II class drugs additionally to therapy, 42 (27,45%) patients underwent MK, and the rest used PUFA. The best clinical effect was found in II class drugs and MK >63,75% and 74,41%, resp. Efficacy of the therapy in this type of patients highly correlated with the improvement of the left ventricle dysfunction, signal-average electrocardiogram, P-wave dispersion and the decrease of the left atrium volume.
Conclusion. If the short-term risk of AF found in MS patients, as primary prevention the method of choice is antiarrhythmic therapy II class drugs and MK.
About the Authors
A. I. Olesin
I.I. Mechnikov North-West State Medical University, Saint-Petersburg
Russian Federation
Russian Federation
V. A. Litvinenko
Elisabeth Hospital, Saint-Petersburg, Russia
Russian Federation
Russian Federation
I. V. Konstantinova
I.I. Mechnikov North-West State Medical University, Saint-Petersburg
Russian Federation
Russian Federation
A. V. Shlapakova
Elisabeth Hospital, Saint-Petersburg, Russia
Russian Federation
Russian Federation
References
1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation — developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14(10): 1385-413.
2. Diagnostics and treatment of ataial fibrillation. National clinical guidelines 5th ed. Moscow: 2012. Russian (Диагностика и лечение фибрилляции предсердий. Национальные клинические рекомендации 5-е издание. М.: 2012).
3. Braunwald’s Heart Disease. A textbook of cardiovascular medicine. 9th ed. Libby P. et al., Phyladelfhia, W. B. Saunders Company; 2011.
4. Olesin AI, Litvinenko VA, Al-Barbari AV, at. el. Atrial fibrillation onset risk in patient with metabolic syndrome: prospective study. Russ J Cardiol, 2014; 12 (116): 25-30.
5. Russian (Олесин А. И., Литвиненко В. А., Аль-барбари А.В. и соавт. Оценка риска развития фибрилляция предсердий у больных метаболическим синдромом: проспективное исследование. Российский кардиологический журнал, 2014; 12 (116): 25-30).
6. Olesin AI, Prosynikova ON. Method for determine risk development of atrial fibrillation. Patent RU № 2497446, 2013. Russian (Олесин А. И., Просяникова О. Н. Способ определения риска развития фибрилляции предсердий. Патент Российской Федерации № 2497446, опубликован 10.11.2013г, Бюллетень изобретений № 31).
7. Olesin AI, Prosynikova ON, Shabrov AV, et al. Method for determining positive effect of modulated kinesotherapy. Patent. № 2286086; 2006. Russian (Олесин А. И., Просяникова О. Н. Шабров А. В. Способ определения эффективности модулированной кинезо-
8. терапии. Патент № 2286086 от 20.06.2006.).
9. Olesin AI, Belova AV, Smolin ZYu. Assessment using modulated kinesitherapy in patient with ishemic heart disease. Russ J Cardiol, 2012; 2: 38-42. Russian (Олесин А. И., Белова А. В., Смолин З. Ю. Возможность использования модулированной кинезотерапии у больных ишемической болезнью сердца. Российский кардиологический журнал, 2012; 2: 38-42).
10. Olesin AI, Smolin ZYu. Assessment using modulated kinesitherapy in patient with ishemic heart disease and atrial fibrillation, and congestive heart failure. European Science and Technology: 3nd International scientific conference. Bildungszentrum Rdk e. V. Wiesbaden, 2012: 510-15.
11. Galito L, Badano L, Fox K, et al. The European Association of Echocardiography (EAE) Textbook of Echocardiography. Oxford Academ.; 2011.
12. Giusti B, Marini M, Rossi L, et al. Gene expression profile of rat left ventricles reveals persisting changes following chronic mild exercise protocol: implications for cardioprotection. BMC Genomics, 2009; 10: 342-55.
13. Gielen S, Schuler G, Adams V. Cardiovascular Effects of Exercise Training: Molecular Mechanisms. Circulation, 2010; 122: 1221-38.
14. Golbidi S, Laher I. Molecular Mechanisms in Exercise-Induced Cardioprotection. Cardiology Research and Practice, 2011; 4: 1-15.
15. Dobrev D, Wehrens XHT. Calmodulin kinase II, sarcoplasmic reticulum Ca2+ leak, and atrial fibrillation. Trends Cardiovasc. Med., 2010; 20(1): 30-34.
16. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA, 2012; 308(5):1024-33.
Review
For citations:
Olesin A.I., Litvinenko V.A., Konstantinova I.V., Shlapakova A.V. A POSSIBILITY TO USE ANTIARRHYTHMIC MEDICATIONS FROM II CLASS AND MODULATED KINESITHERAPY AS PRIMARY PREVENTION OF ATRIAL FIBRILLATION IN METABOLIC SYNDROME PATIENTS. Russian Journal of Cardiology. 2015;(11):75-80. (In Russ.) https://doi.org/10.15829/1560-4071-2015-11-75-80
Views:
451
Email this article 